<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03246776</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingFH20170801</org_study_id>
    <nct_id>NCT03246776</nct_id>
  </id_info>
  <brief_title>Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan</brief_title>
  <acronym>MCCK</acronym>
  <official_title>The Clinical Study of the Microbial Colonization of Chronic Keratinized Hand Eczema and the Change of Microbial Colonization After External Using of Halometasone Triclosan Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study of the microbial colonization of chronic keratinized hand eczema and the
      change of microbial colonization after external using of Halometasone Triclosan Cream
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study of the microbial colonization of chronic keratinized hand eczema and the
      change of microbial colonization after external using of Halometasone Triclosan Cream
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2017</start_date>
  <completion_date type="Actual">December 8, 2017</completion_date>
  <primary_completion_date type="Actual">December 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Hand eczema severity</measure>
    <time_frame>2 weeks</time_frame>
    <description>HEES(hand eczema extent score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment/Hand eczema severity</measure>
    <time_frame>2 weeks</time_frame>
    <description>Photographic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator reported improvement</measure>
    <time_frame>2 weeks</time_frame>
    <description>IGA(investigator's global assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment/Hand eczema severity</measure>
    <time_frame>2 weeks</time_frame>
    <description>Dermatoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Quality of Life</measure>
    <time_frame>week 0 and 2</time_frame>
    <description>questionnaire :DLQI(dermatology life quality index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Improvement</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>VAS(Visual Analog Score for pruritus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment/Hand eczema severity</measure>
    <time_frame>2 weeks</time_frame>
    <description>HECSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Microbial Colonization rates</measure>
    <time_frame>2 weeks</time_frame>
    <description>Staphylococcus aureus colonization rates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Chronic Hand Eczema</condition>
  <arm_group>
    <arm_group_label>Halometasone Triclosan Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive external Use of Halometasone Triclosan Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Halometasone Triclosan</intervention_name>
    <description>Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment</description>
    <arm_group_label>Halometasone Triclosan Cream</arm_group_label>
    <other_name>regular moisturizer</other_name>
    <other_name>wet wrap bandage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Chronic Keratinized hand eczema for at least 3 months

          -  The affected area is greater than 30%

          -  Overall assessment of the severity of the disease(IGA)≥3 OR HEES≥13

          -  No obvious incentive .Who have read the instructions of the subject, agreed to and
             signed written informed consent, and have been able to provide a personal medical
             history.

        Exclusion Criteria:

          -  Pregnancy, breast feeding

          -  Severe liver and kidney disease, blood system disease, autoimmune disease, chronic
             severe infection, diabetes, mental illness, drug use, alcohol abuse, etc

          -  Malignant neoplasms or other serious maladies that may affect the correct assessment
             of efficacy

          -  Topical corticosteroid was suspended for less than 2 weeks;The system used
             corticosteroids and other immunosuppressive agents (thunder vine and other drugs)
             which were suspended for less than four weeks

          -  Eczema of the facial and skin creases

          -  Atopic dermatitis, contact dermatitis, blister hand eczema, contact urticaria, discoid
             eczema

          -  participated in other clinical trials within 3 months.

          -  Known sensitivity to Halometasone Triclosan

          -  failure to follow the prescribed medication or the incomplete record of the test
             process which will affect the curative effect judgment

          -  Other reasons why researchers think they should not be included
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>linfeng li, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Wei Xu</investigator_full_name>
    <investigator_title>associated professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triclosan</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

